Trial Profile

Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 23 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Colchicine (Primary) ; Edoxaban (Primary)
Indications COVID 2019 infections; Deep vein thrombosis; Ischaemic stroke; Myocardial infarction; Pulmonary embolism; SARS-CoV-2 acute respiratory disease; Thrombosis
Focus Therapeutic Use
Acronyms CONVINCE

Most Recent Events

02 Sep 2022 Status changed from recruiting to discontinued due to insufficient rate of patient accrual and newly available scientific evidence.
22 Jul 2021 Planned End Date changed from 31 Dec 2021 to 30 Jun 2023.
22 Jul 2021 Planned primary completion date changed from 1 Oct 2021 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com